AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01332890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequence 5
Description: Period1(B) Period2(A) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
Study NCT01332890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequence 6
Description: Period1(A) Period2(C) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
Study NCT02134210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Head-to-head comparison
Study NCT02134210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-0214
Study NCT04551196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alternating Acetaminophen and Ibuprofen
Description: Subjects will alternate their post-operative acetaminophen and ibuprofen every 3 hours.
Study NCT04551196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Acetaminophen and Ibuprofen
Description: Subjects will take their post-operative acetaminophen and ibuprofen together every 6 hours.
Study NCT00244374 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A & B vaccine
Description: Each subject will receive a total of 4 immunizations over 6 months on a 0-1-2-6 month schedule. At the initial visit, subjects>18 years of age will receive the Twinrix vaccine and subjects\<18 years of age will receive the Engerix-B vaccine. Cohort subjects>18 years found to have HAV antibody at screening will receive Engerix-B for their remaining 3 immunizations. All subjects will receive: an immunization record with the first vaccine dose entered and the dates the next doses are due; helpful hints for remembering vaccine appointments; and written instructions on where and how to get immunized outside of SF.
Study NCT00244374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach
Description: Outreach worker vaccine adherence support: Half of cohort subjects will be assigned to outreach worker vaccine adherence support and will meet with their outreach workers from Haight Ashbury Youth Outreach Team (HAYOT) and Glide Health Services on the day of vaccine cohort study enrollment. Intensive vaccination tracking and in-person outreach support will begin one week before the second and third vaccine doses are due, and again two weeks before the fourth dose is due.
Study NCT00244374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIC
Description: The Adult Immunization Clinic (AIC) is a public low-cost vaccine clinic located centrally at 101 Grove Street in the lobby of the San Francisco Department of Public Health (SFDPH). The clinic is open from Monday-Friday 9 a.m. to 4 p.m. Nurses at the AIC will be available 40 hours/week to administer free immunizations to study subjects.
Study NCT00244374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEP
Description: Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6. Research nurses will provide 16 hours/week of vaccine administration services at SEPs well attended by young IDU. The San Francisco Needle Exchange (SFNE) serves primarily youth and young adults on Mondays, Wednesdays, and Fridays from 5-7 p.m. in an indoor location in the Haight-Ashbury district. A study nurse will be at SFNE for a total of 6 hours per week. HIV Prevention Project (HPP) sites also operate for 2 hrs each (Tues, Thu, Fri, Sat). Medical services are provided either in a clinic setting at indoor sites (6th Street) or at outdoor sites (Hemlock Alley, Duboce). A study nurse will attend each of these 5 weekly sites for a total of 10 hours/week.
Study NCT02350920 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Committment Therapy (ACT)
Description: This intervention will run with 12-15 participants in each group for a duration of 8 weeks. Each group session will last 1-1.5 hours.
Study NCT01982877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Four Supports Intervention
Description: The Four Supports Intervention is a multi-faceted intervention involving the addition of a trained nurse/social worker interventionist to the patient's care team who delivers four kinds of support: emotional support, communication support, decision support, and anticipatory grief support.
Study NCT01982877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Control Intervention
Description: In addition to usual care, enrolled surrogates will receive two 15-minute education sessions about critical illness and mechanical ventilation on days 2 and 5, delivered by a research staff coordinator with education in critical care nursing.
Study NCT02527837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium nitrite
Description: Sodium nitrite, 240 micrograms/kg/hour for 2 hours
Study NCT02527837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Sodium chloride, isotonic 0.9%, 25 ml/hour for 2 hours
Study NCT03083392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: treatment of chronic maxillary sinusitis using DIVA system
Description: chronic maxillary sinusitis treatment utilizing DIVA system for antral lavage
Study NCT03083392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dynamic implant valve approach - DIVA system
Description: The DIVA system will be used to apply saline lavage to the maxillary sinus
Study NCT02970032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Real time heparin dose adjustment
Description: Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
Study NCT02970032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard heparin dose
Description: Patients will be placed on heparin infusions per their surgeon's discretion.
Study NCT00561444 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires taking 20 minutes to complete.
Study NCT01086605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pixantrone dimaleate
Description: Given IV
Study NCT03601455 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT03368885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal dietary diversity
Description: Counsel pregnant women for proper dietary intake and create awareness among family members and community to support her on maternal nutrition
Study NCT03368885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet diversity in complementary feeding
Description: Counsel mothers of children of 6-23 months on diet diversity in complementary feeding by demonstration during home-visits and seek support from father and family members
Study NCT03601455 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT03601455 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study NCT00957931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation
Description: Bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.
Study NCT03368885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exclusive Breast Feeding
Description: Counselling on exclusive breast feeding among children under 6 months-Provide information to mothers of children of 3-6 months for exclusive breast feeding through home visits, and mothers meetings
Study NCT00957931 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Cells
Study NCT04178538 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation
Description: ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation with all inside technique
Study NCT04178538 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard ACL reconstruction with all inside technique
Description: Standard ACL reconstruction with all inside technique
Study NCT02409550 — intervention group
Intervention type: OTHER
Intervention: CARATKids Questionnaire
Study NCT00720902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood draws
Description: Subjects will have serum cardiovascular markers assessed
Study NCT00720902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: growth hormone releasing hormone (GHRH) & arginine
Description: Subjects will receive GHRH and arginine intravenously and then have blood drawn at frequent intervals over a 90 minutes to assess growth hormone secretion.
Study NCT00720902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid ultrasound
Description: Subjects will have an ultrasound of their neck to assess their carotid arteries to look for intima-medial thickness.
Study NCT00720902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Subjects will have MRI and MR spectroscopy of the abdomen and lower extremities to assess for fat in internal organs and muscle.
Study NCT00720902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endothelial cell biopsy
Description: Subjects will undergo endothelial cell biopsies to harvest endothelial cells to study. It will occur once and takes approximately 20 minutes. Patients will have an iv placed and then a sterile wire is passed back and forth in the iv a couple of times. Three wires are passed.
Study NCT01879423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine Dispersible/Chewable tablets 5mg*5
Description: Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg\*1 tablet at Day15
Study NCT01879423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine Compressed tablet 25mg
Description: Single dose of lamotrigine compressed 25mg\*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day15
Study NCT04968262 — intervention group
Intervention type: OTHER
Intervention: Sepsis therapy
Description: Patients receiving sepsis therapy followed the international guidelines of the 2016 Surviving Sepsis Campaign regarding fluid resuscitation, feeding, vasopressor, respiratory, anticoagulation and hydrocortisone therapy, along with ulcer prophylaxis and sedation. Blood and urine samples were collected at the intensive care unit from this patient group at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up. 24 patients were documented without sepsis and acute kidney injury as a control group.
Study NCT04968262 — intervention group
Intervention type: OTHER
Intervention: Sepsis-related acute kidney injury therapy
Description: Patient management of sepsis and sepsis-related acute kidney injury followed the international guidelines of the 2016 Surviving Sepsis Campaign regarding fluid resuscitation, feeding, vasopressor, respiratory, anticoagulation and hydrocortisone therapy, along with ulcer prophylaxis, sedation and renal replacement therapy (if needed). In this patient group, blood and urine sampling was performed at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up.
Study NCT00054964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol HFA-BOI
Description: Albuterol HFA breath operated inhaler, 90 mcg/sprau
Study NCT00054964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol HFA-MDI
Description: Albuterol HFA multi-dose inhaler
Study NCT03462706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold Snare
Description: Subjects randomized to Cold Snare Intervention will have any polyps sized 6mm to 15mm removed using cold snare techniques (no electrocautery, no submucosal injection.)
Study NCT03462706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hot Snare
Description: Subjects randomized to Hot Snare Intervention will have any polyps sized 6mm to 15mm removed using hot snare techniques (with electrocautery, no submucosal injection.)
Study NCT03462706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold EMR
Description: Subjects randomized to Cold EMR will have any polyps sized 6mm to 15mm removed using cold EMR techniques (no electrocautery, with submucosal injection.)
Study NCT03462706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hot EMR
Description: Subjects randomized to Hot EMR will have any polyps sized 6mm to 15mm removed using hot EMR techniques (with electrocautery, with submucosal injection.)
Study NCT04805463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: The group that did not undergo any procedure after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied to the wound area.
Study NCT04805463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRF group
Description: The group in which PRF is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA)was applied over the PRF.
Study NCT04805463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGF group
Description: The group in which CGF is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied over the CGF.
Study NCT04805463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AFG group
Description: The group in which AFG is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied over the AFG.
Study NCT05260372 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantification of donor-derived cell-free DNA
Description: Quantification of ddcfDNA on serial plasma samples during follow-up after lung transplantation
Study NCT01411501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Thrust and lift the needle to achieve De Qi. After being needled, the points will be punctured again using auxiliary needles 2 mm lateral to the first needle, and to a depth of 2 mm without manual stimulation. Put the electric stimulator on the pair of needles with a continuous wave, 20Hz. The current intensity is increased to the patients' maximum tolerance and then slightly reduced to a bearable level (0.1-1.0 mA).~Huatuo Brand needle (φ0.30×25mm,φ0.30×40mm,φ0.30×50mm, produced by Suzhou Medical Appliance Factory) and G6805-1A electro-acupuncture apparatus(produced by Shanghai Huayi Medical Instrument Co. Ltd.) will be used.~Five sessions/week in the first 2 weeks, three sessions/week for in the last 2 weeks.
Study NCT01411501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mosapride citrate
Description: 4-week oral use of mosapride citrate, 5mg, three times daily 0.5 hour before meal
Study NCT02231229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCR-based strategy
Description: Treatment based on the results of detection of resistance to isoniazid and rifampicin using PCR (GenoType ® Mycobacterium Tuberculosis Drug Resistance (MTBDR)plus 2.0) in a smear positive patient with pulmonary tuberculosis: initiation of a 3 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA)) if no resistance is detected and treatment based on suspected resistance in case of INH and/or RIF resistant strain.
Study NCT02231229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Initiation of a standard 4 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA); ethambutol (EMB or E)) until the results of DST are available.
Study NCT03842462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP
Description: infants receive primary non-invasive respiratory support by mean of nCPAP
Study NCT03842462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: infants receive primary non-invasive respiratory support by mean of NIPPV
Study NCT03842462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NHFOV
Description: infants receive primary non-invasive respiratory support by mean of NHFOV
Study NCT01062763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spironolactone
Description: 25 to 50 mg once daily
Study NCT03368885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community mobilization
Description: Engagement of local/religious leader, husbands to support diet diversity for pregnant women and doctors and fathers to support diet diversity for complementary feeding
Study NCT03368885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capacity Building
Description: Capacity Building-Training of Community mobilization coordinator and mentoring for knowledge enhancement on nutrition for pregnant women and children below 2 years
Study NCT01062763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: addition of placebo 1 to 2 tablets daily
Study NCT01712243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light
Study NCT01712243 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light
Study NCT01403441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiosurgical Neuromodulation using the Cyberknife
Description: our team has selected 60 Gray (Gy) as the dose to the target margin to be used for radiosurgical neuromodulation in patients with intractable bipolar disorder; the target being the anterior cingulate (Cg) that correlates with Brodmann area 25 (Cg25).
Study NCT02542540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training with Nintendo Wii console
Description: Children with OI and draining for 3 months using Nintendo Wii console
Study NCT02020980 — intervention group
Intervention type: BIOLOGICAL
Intervention: Botulinum toxin type A
Description: This is an observational study designed to reflect the clinical practice in real life as closely as possible.~Botulinum Toxin Type A (BoNT-A) injection administered according to the local Summary of Product Characteristics (SmPC) and the locally agreed treatment guidelines.
Study NCT02896816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surface EMG, MRI and PET Scan
Description: It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed. In addition, individuals with Parkinson's disease will undergo brain scans at Massachusetts General Hospital to examine whether there are any relationships between muscle activity and brain function.
Study NCT02896816 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surface EMG
Description: It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed.
Study NCT01556698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVN1000
Study NCT01556698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Placebo
Study NCT02392611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alobresib
Description: Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle
Study NCT02392611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Tablets administered orally once daily on Cycle 1 Day 1 of 28 days cycle
Study NCT02392611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered intramuscularly on Cycle 1 Day 1 of 28 days cycle and every 28 days
Study NCT00847821 — intervention group
Intervention type: DRUG
Intervention: Bazedoxifene 10 mg/CE 0.625 mg
Description: No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
Study NCT00847821 — intervention group
Intervention type: DRUG
Intervention: Bazedoxifene 20 mg/CE 0.625 mg
Description: No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
Study NCT00847821 — intervention group
Intervention type: DRUG
Intervention: Bazedoxifene 40 mg/CE 0.625 mg
Description: No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.